Medical News

RSS

Chemotherapy delivered directly into liver blood vessels increases progression-free survival in melanoma patients

Patients undergoing treatment for melanoma that has spread to the liver may respond well to chemotherapy delivered directly into the liver's blood vessels, according to a study sponsored by the National Cancer Institute and Delcath Systems Inc., and led by James F. Pingpank, M.D., associate professor of surgery, University of Pittsburgh School of Medicine, and surgical oncologist with UPMC Cancer Centers. The results will be disclosed in an oral presentation on June 5 in Chicago at the 46th annual meeting of the American Society of Clinical Oncology (ASCO).

7 Jun 2010

Allos Therapeutics reports data from PROPEL trial of FOLOTYN in patients with PTCL

Allos Therapeutics, Inc. today reported new analyses of data from the Company's pivotal PROPEL trial of FOLOTYN (pralatrexate injection) in patients with relapsed or refractory peripheral T-cell lymphoma.

7 Jun 2010

The Iacocca Family Foundation and Kineta partner to develop Type 1 diabetes mellitus drug

Kineta, Inc. joined with The Iacocca Family Foundation today to announce a new investment partnership to speed development of Kineta's preclinical autoimmune drug candidate - ShK-186 - and its multiple applications to treat Type 1 diabetes mellitus.

7 Jun 2010

Economic, clinical benefits of HyperQ stress test presented at International Congress on Electrocardiology

BSP Biological Signal Processing Ltd., develops and markets innovative systems for non-invasive diagnosis and monitoring of Ischemic Heart Disease based on its proprietary HyperQ technology. BSP recently presented the results of a study on the economic and clinical benefits of the HyperQ stress test in the diagnosis and management of coronary heart disease at the International Congress on Electrocardiology on June 4th, 2010.

7 Jun 2010

Eisai's eribulin mesylate improves median OS compared with TPC in pre-treated metastatic breast cancer patients

Results of a Phase III study presented today at the American Society of Clinical Oncology (ASCO) Annual Meeting showed that Eisai's eribulin mesylate significantly improved median overall survival (OS) compared with Treatment of Physician's Choice (TPC) in heavily pre-treated metastatic breast cancer patients.

7 Jun 2010

Bisphosphonates may cause poorer survival rate in women with early stage breast cancer: Study

Scientists from the Barbara Ann Karmanos Cancer Institute in Detroit presented preliminary data that shows nitrogen-containing bisphosphonates, therapeutic agents used to promote bone health and inhibit resorption, may cause a slightly poorer survival rate in post-menopausal women with early stage breast cancer who take them for their anti-osteoporosis properties.

7 Jun 2010

Exelixis reports updated interim data from trials of XL765 small molecule inhibitor of PI3K and mTOR

Exelixis, Inc. today reported updated interim data from three ongoing trials of XL765 (SAR245409), an orally available small molecule inhibitor of phosphoinositide-3-kinase (PI3K) and mTOR. Activation of the PI3K pathway is a frequent event in human tumors, promoting cell proliferation, survival, and resistance to chemotherapy and radiotherapy.

7 Jun 2010

GRASP program reduces depression symptoms, boosts physical therapy results in stroke patients

You don't always need to build up a big sweat to reap the healing benefits of physical activity. Research has found that even a low-intense exercise program can reduce depression symptoms and boost physical therapy results in recovering stroke patients.

7 Jun 2010

Tranzyme Pharma receives BioQuébec's 2010 Genesis Award for "Innovation"

Tranzyme Pharma, a clinical-stage biopharmaceutical company, announced today that the Company has been awarded BioQuébec's 2010 Genesis Award for "Innovation", having demonstrated strong and proven innovation in the field of life sciences.

7 Jun 2010

Ipilimumab extends survival of metastatic melanoma patients: Study

A therapy that multiplies the effect of a natural disease-fighting antibody has extended the lives of patients with metastatic melanoma in a large, international clinical trial. The study's researchers will report their findings simultaneously at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago and in the New England Journal of Medicine.

7 Jun 2010

Updated phase II study results of OPAXIO in patients with advanced esophageal cancer

Cell Therapeutics, Inc. announced today that updated phase II study results of OPAXIO (paclitaxel poliglumex) in patients with advanced esophageal cancer demonstrated that 38% (15/40) patients receiving OPAXIO in combination with cisplatin and concurrent radiation achieved a pathologic or endoscopic complete response.

7 Jun 2010

Misys, SmartStream Technologies partner to improve trade lifecycle management

Misys plc, the global application software and services company, today announces that it has partnered with SmartStream Technologies to deliver improved risk control and greater efficiency across the entire trade transaction lifecycle.

7 Jun 2010

MSKCC researchers study novel approach to treat metastatic melanoma

Physician-scientists at Memorial Sloan-Kettering Cancer Center are studying a novel approach to treat metastatic melanoma, known as immunotherapy, which uses the body's own immune system to attack cancer. Presented today at the American Society of Clinical Oncology annual meeting, encouraging new data shows - for the first time - a survival benefit in metastatic melanoma patients using an immunotherapy discovered and clinically investigated by researchers at Memorial Sloan-Kettering.

7 Jun 2010

Phase I study results of Pharmacyclics' PCI-32765 Btk inhibitor for B cell NHL presented at ASCO

Pharmacyclics, Inc. today announced results from a Phase I study of its novel orally administered Bruton's tyrosine kinase (Btk) inhibitor, PCI-32765, in patients with relapsed or refractory B cell non-Hodgkin's lymphoma (NHL) including chronic lymphocytic leukemia (CLL) and Waldenstroms Macroglobulinemia (WM). These data are being presented at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place this week in Chicago, IL.

7 Jun 2010

MD Anderson-led Phase III clinical study determines Sprycel superior to Gleevec as front-line therapy

Dasatanib, a medication currently approved as treatment for drug-resistant chronic myeloid leukemia, provided patients with quicker, better responses as a first therapy than the existing front-line drug, according to researchers at The University of Texas MD Anderson Cancer Center.

7 Jun 2010

Telemedicine holds key to rehabilitation of people with stroke: Researcher

Telemedicine holds the key to the rehabilitation of people with stroke living in northern, rural, remote Canadian communities, rehabilitation researcher Esmé French told the Canadian Stroke Congress today.

7 Jun 2010

Smoke-free laws protect both children and adults from exposure to secondhand smoke

Researchers at the Harvard School of Public Health (HSPH) have found that children and adolescents living in non-smoking homes in counties with laws promoting smoke-free public places have significantly lower levels of a common biomarker of secondhand smoke exposure than those living in counties with no smoke-free laws.

7 Jun 2010

Kaiser Permanente earns perfect 100% rating on Healthcare Equality Index

Kaiser Permanente is the first health and hospital system to earn a perfect 100 percent rating on the Healthcare Equality Index. The HEI is an annual survey administered by the Human Rights Campaign Foundation and Gay and Lesbian Medical Association.

7 Jun 2010

Seasonal allergies may cause mild sleep-disordered breathing in young children: Research

The prevalence of mild sleep-disordered breathing in young children may fluctuate seasonally, suggests a research abstract that will be presented Monday, June 7, 2010, in San Antonio, Texas, at SLEEP 2010, the 24th annual meeting of the Associated Professional Sleep Societies LLC.

7 Jun 2010

Phase 3 trial demonstrates superiority of Amgen's denosumab over Zometa in preventing SREs

Amgen today announced detailed results from a Phase 3, head-to-head trial which compared the efficacy and safety of denosumab versus Zometa® (zoledronic acid) in 1,901 patients with hormone-refractory prostate cancer and bone metastases. The study met its primary and secondary endpoints and demonstrated denosumab's superiority over Zometa in delaying or preventing skeletal related events (SREs).

7 Jun 2010

Medical News

Chemotherapy delivered directly into liver blood vessels increases progression-free survival in melanoma patients

Allos Therapeutics reports data from PROPEL trial of FOLOTYN in patients with PTCL

The Iacocca Family Foundation and Kineta partner to develop Type 1 diabetes mellitus drug

Economic, clinical benefits of HyperQ stress test presented at International Congress on Electrocardiology

Eisai's eribulin mesylate improves median OS compared with TPC in pre-treated metastatic breast cancer patients

Bisphosphonates may cause poorer survival rate in women with early stage breast cancer: Study

Exelixis reports updated interim data from trials of XL765 small molecule inhibitor of PI3K and mTOR

GRASP program reduces depression symptoms, boosts physical therapy results in stroke patients

Tranzyme Pharma receives BioQuébec's 2010 Genesis Award for "Innovation"

Ipilimumab extends survival of metastatic melanoma patients: Study

Updated phase II study results of OPAXIO in patients with advanced esophageal cancer

Misys, SmartStream Technologies partner to improve trade lifecycle management

MSKCC researchers study novel approach to treat metastatic melanoma

Phase I study results of Pharmacyclics' PCI-32765 Btk inhibitor for B cell NHL presented at ASCO

MD Anderson-led Phase III clinical study determines Sprycel superior to Gleevec as front-line therapy

Telemedicine holds key to rehabilitation of people with stroke: Researcher

Smoke-free laws protect both children and adults from exposure to secondhand smoke

Kaiser Permanente earns perfect 100% rating on Healthcare Equality Index

Seasonal allergies may cause mild sleep-disordered breathing in young children: Research

Phase 3 trial demonstrates superiority of Amgen's denosumab over Zometa in preventing SREs

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Shaping the future of lab automation through AI and robotics

Latest News